Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis

Clara De Simone, Magda D'Agostino, Rodolfo Capizzi, Angela Capponi, Antonio Venier, Giacomo Caldarola

Risultato della ricerca: Contributo in rivistaArticolo in rivista

23 Citazioni (Scopus)

Abstract

The combination of etanercept, a tumour necrosis factor α inhibitor, with narrow-band ultraviolet B (NB-UVB) phototherapy has recently been reported to be effective in moderate-to-severe plaque psoriasis, yielding better results than either monotherapy. To assess the efficacy and safety of this combined treatment using the lower approved etanercept dosage. In this single-arm open-label study patients received etanercept 50 mg once weekly combined with NB-UVB phototherapy three times weekly for 8 weeks, followed by etanercept alone until week 12. We evaluated the proportion of patients achieving 75%, 90% and 100% improvement of their initial PASI score (PASI75, PASI90, and PASI100, respectively). Patients were 19 men and 14 women, mean age 48.3 years ± 12.1 standard deviation (SD) and mean baseline Psoriasis Area and Severity Index (PASI) score 22.5 ± 7.5. On treatment weeks 4, 8, and 12, 24.2%, 66.7%, and 81.8% of patients achieved PASI75; 8.0%, 15.1%, and 57.6% reached PASI90, and 0%, 6.0%, and 24.2% attained PASI100, respectively. There were no severe side effects. Low-dosage etanercept combined with NB-UVB phototherapy is an effective, safe and economical approach to treat moderate-to-severe plaque psoriasis. Further studies are clearly required to assess its long-term efficacy and safety.
Lingua originaleEnglish
pagine (da-a)568-572
Numero di pagine5
RivistaEuropean Journal of Dermatology
Volume21
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Anti-Inflammatory Agents, Non-Steroidal
  • Chronic Disease
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunoglobulin G
  • Male
  • Middle Aged
  • Psoriasis
  • Quality of Life
  • Receptors, Tumor Necrosis Factor
  • Treatment Outcome
  • Ultraviolet Therapy

Fingerprint Entra nei temi di ricerca di 'Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis'. Insieme formano una fingerprint unica.

Cita questo